|Bid||72.91 x 800|
|Ask||74.25 x 1000|
|Day's range||71.71 - 81.58|
|52-week range||66.38 - 331.68|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||250.00|
‘A Shot to Save the World’ author, Gregory Zuckerman joins 'Influencers with Andy Serwer' to discuss the Trump Administration's role in developing the COVID-19 vaccines.
Investors appear to be concerned about Pfizer's and BioNTech's head start in developing an omicron-specific vaccine.
The road to FDA approval can be long, and in the case of COVID-19 vaccines, there is no time for delays and no room for error. One company that has come to understand this very well is Novavax (NASDAQ: NVAX). Since 2020, the company has been developing a vaccine to help prevent and fight the impact of COVID-19.